Evidence map›Paper›PMID 29499171›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2018

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.

Oskar Hansson, John Seibyl, Erik Stomrud, Henrik Zetterberg, John Q Trojanowski, Tobias Bittner, Valeria Lifke, Veronika Corradini, Udo Eichenlaub, Richard Batrla and 7 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 491 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
491citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

491 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. The value of timely treatment with anti-amyloid therapy for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Vulnerability of locus coeruleus connections to aging and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article

431 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Oskar HanssonClinical Memory Research Unit, Lund University, Malmö, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden. Electronic address: oskar.hansson@med.lu.se.
John SeibylInstitute for Neurodegenerative Disorders, New Haven, CT, USA.
Erik StomrudClinical Memory Research Unit, Lund University, Malmö, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Henrik ZetterbergClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute, London, UK.
John Q TrojanowskiCenter for Neurodegenerative Disease Research, Institute on Aging and Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA.
Tobias BittnerFormer Employee of Roche Diagnostics GmbH, Penzberg, Germany.
Valeria LifkeRoche Diagnostics GmbH, Penzberg, Germany.
Veronika CorradiniRoche Diagnostics International, Rotkreuz, Switzerland.
Udo EichenlaubRoche Diagnostics GmbH, Penzberg, Germany.
Richard BatrlaRoche Diagnostics International, Rotkreuz, Switzerland.
Katharina BuckRoche Diagnostics GmbH, Penzberg, Germany.
Katharina ZinkRoche Diagnostics GmbH, Penzberg, Germany.
Christina RabeFormer Employee of Roche Diagnostics GmbH, Penzberg, Germany.
Kaj BlennowClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden. Electronic address: Kaj.Blennow@neuro.gu.se.
Leslie M ShawDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: Les.Shaw@uphs.upenn.edu.
Swedish BioFINDER study group
Alzheimer's Disease Neuroimaging Initiative

Funding

UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
NIA NIH HHS P30 AG010124
6 · The paper itself

Abstract

introductionWe studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort.

methodsCutoffs for Elecsys amyloid-β

resultsCSF total tau/Aβ(1-42) and phosphorylated tau/Aβ(1-42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer's Disease Neuroimaging Initiative (overall percent agreement: 89%-90%; area under the curves: 96%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/Aβ ratios were as accurate as semiquantitative PET image assessment in predicting visual read-based outcomes. DISCUSSION: Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis.

Indexed as

ImmunoassayPositron-Emission TomographyAgedAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsAutomation, LaboratoryBiomarkersCognitive DysfunctionCohort StudiesDisease ProgressionEthylene GlycolsFemaleHumansMaleRadiopharmaceuticalsAmyloid beta-PeptidesAniline CompoundsBiomarkersEthylene GlycolsflorbetapirMAPT protein, humanRadiopharmaceuticalstau ProteinsAmyloid PET concordanceAmyloid-β (1–42)Biomarker validationClinical progressionCSF biomarkersCutoffsPhosphorylated tau (pTau)Total tau (tTau)

Identifiers

PMID29499171
PMCPMC6119541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.